Atlas Trials

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

Clinical trial NCT03314324 · COMPLETED

Trial details

NCT number
NCT03314324
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Castrate-resistant Prostate (CRPC) Cancer
Start date
2017-11-29
Primary completion
2022-01-31
Enrollment
250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.